Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Health Daily.
Press releases published on August 13, 2025
Applied Therapeutics Reports Second Quarter 2025 Financial Results
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT- …
PharmaCorp Rx Inc. Announces New Credit Facilities With CIBC and Unveils Pharmacist Co-Ownership Financing Initiative
SASKATOON, Saskatchewan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a credit agreement with Canadian Imperial Bank of Commerce (“CIBC”) providing the …
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs Consummation of acquisition expected …
rYojbaba Co., Ltd. Announces Pricing of $5 Million Initial Public Offering of Japanese Common Shares and Listing on Nasdaq
FUKUOKA, Japan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the pricing of its initial public offering of 1,250,000 Japanese common shares at …
2025 Winners of the 31st-Annual Eric Dostie Memorial College Scholarship Announced
TEMECULA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nufactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., is pleased to announce the names of its 2025 Eric Dostie Memorial College Scholarship recipients. The annual scholarship …
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable …
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market …
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types …
KBR Awarded an Estimated $2.459 Billion Contract to Support Astronaut Health and Performance for Space Missions
HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) announced today it has been awarded an estimated $2.459 billion NASA contract to support astronaut health, occupational health, and research that could help mitigate health risks for future human …
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to …
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell …
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 …
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the …
Codexis Reports Second Quarter 2025 Financial Results
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to …
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC …
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing …
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster …
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE …
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …